HomeTrending StocksAditx Therapeutics Inc. (ADTX) stock surges during current market. Here’s to know...

Aditx Therapeutics Inc. (ADTX) stock surges during current market. Here’s to know why?

Aditx Therapeutics Inc. (NASDAQ: ADTX) stock gains by 4% during the current market trading session. Aditxt is working on technologies aimed at enhancing the immune system’s health through immunological surveillance and reprogramming. The immune monitoring technology developed by Aditxt is intended to offer a thorough profile of the immune system that is tailored to the individual.

>> 7 Top Picks for the Post-Pandemic Economy << 

What is happening?

AditxtScore for COVID-19 has been enhanced, according to Aditx. AditxtScore for COVID-19 is a multi-dimensional immune response test that detects multiple combinations of antibody responses against many specific antigens, has been improved to include a high-sensitivity neutralizing antibody diagnostic, allowing doctors to evaluate a person’s immune system response to the SARS-CoV-2 virus.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Read More

AditxtScore for COVID-19, which was initially released in August of 2020, differs from standard antibody tests in that it provides a comprehensive picture of a persons’ immune response to numerous antigens linked to the SARS-CoV-2 virus. This multi-multiplex technique to collecting the complete range of SARS-CoV-2 biomarkers in a single test cycle provides a very comprehensive image of an individual’s immune response. AditxtScore for COVID-19 now incorporates the ability to detect neutralizing antibodies, which are a subset of virus-specific antibodies that prevent infection by dealing with viral particle entrance into cells.

Amro Albanna, Co-founder and Chief Executive Officer of Aditxt stated,

Every person’s immunological response is unique to them. Individual immunological responses to COVID-19 and COVID-19 vaccination have been studied, and they have discovered that the immediacy, intensity, and durability of antibody responses can vary greatly depending on a variety of factors. This new AditxtScore for COVID-19 gathers crucial information on how efficient an individual’s antibodies are in inactivating the virus. They think that when more people are vaccinated or infected with the virus, AditxtScore for COVID-19 with neutralizing antibody diagnostics will provide more comprehensive information about the quality of the immune response to the virus.

Related Videos

Must Read

Related News


Please enter your comment!
Please enter your name here